Some experiments have constructed bispecific T cell-binding antibodies that can bind CD3 or CD28, and in a humanized mouse model, stimulation of CD3 and CD28 was found to inhibit tumor growth, stimulate the proliferation of memory/effector T cells, and reduce regulatory T cells in non-human primates at a well-tolerated dose. Here, CD28 is linked to neoplasm.